Mylan
Sign in to saveAlso known as Mylan N.V., Mylan Inc., Mylan (United States)
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
Key facts
- Company.name
- Mylan N.V.
- Company.logo
- Mylan Logo.svg
- Company.logo_size
- 250px
- Company.trade_name
- Mylan N.V.
- Company.former_name
- Milan
- Company.type
- Public
- Company.industry
- Pharmaceuticals
- Company.founded
- in White Sulphur Springs, West Virginia, United States
- Company.founders
- Milan PuskarDon Panoz
- Company.fate
- Merged with Upjohn to form Viatris
- Company.successor
- Viatris
- Company.hq_location_city
- Hatfield, Hertfordshire
- Company.hq_location_country
- United Kingdom
- Company.products
- Generic and specialty pharmaceuticals and active pharmaceutical ingredients
- Company.divisions
- see Operations
via Wikipedia infobox
Research organization · ROR
- Type
- Company, Funder
- Founded
- 1961
- Location
- Canonsburg, United States
- Also known as
- UDL Laboratories, Inc.
- Status
- Inactive
GRID grid.476548.c
Official website
Mylan - Now a Part of Viatris
mylan.com →Link to the official site · 424 chars · not written by Vinony
Wikidata facts
- Official name
- Mylan N.V.
- Employees
- 35000
- Official website
- www.mylan.com
Show 6 more facts
- inception
- 1961-01-01
- Commons category
- Mylan
- native label
- Mylan
- market capitalization
- 21200000000
- dissolved, abolished or demolished date
- 2020-11-00
- social media followers
- 11192
Sources (7)
via Wikidata · CC0
~28 min read
Article
36 sectionsContents
- Corporate headquarters
- Stock
- History
- Founding to 1980
- 1980s
- Dyazide & Maxzide
- Acquisitions begin
- 1990s
- 2000s
- Attempted King Pharmaceuticals acquisition
- Matrix acquisition
- EpiPen acquisition
- 2010s
- Generic Advair agreement
- EpiPen4Schools launch
- Agila acquisition
- Abbott acquisition
- Attempted Perrigo acquisition
- Attempted purchase by Teva
- New COPD drug
- Meda acquisition
- Valsartan recall
- Generic Advair approval
- Merger with Pfizer's off-patent drug business and name change to Viatris
- Stock
- Acquisition history
- Criticism
- EpiPen pricing
- Executive pay
- Execution drugs
- Products
- Generic Medicines
- Branded Medicines
- Management
- References
- External links
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, the company grew from the third-largest generic and specialty pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.